



## Pamela Kearns

Pamela Kearns is Professor of Clinical Paediatric Oncology at the Institute of Cancer and Genomic Sciences, University of Birmingham and Honorary Consultant in Paediatric Oncology at Birmingham Children's Hospital and Director of the University of Birmingham's UKCRC registered, Cancer Research UK Clinical Trials Unit, delivering a wide-ranging programme of clinical trials across all types of cancer in all age groups, notably leading the National Children's Cancer Trials Team responsible the vast majority of UK's clinical trial portfolio for children and young people with cancer. In 2015, she was appointed as a Senior Clinical Advisor to Cancer Research UK (CRUK).

In 1982, Professor Kearns was awarded a BSc (Hons) in Physiology from the University of Aberdeen where she subsequently studied Medicine qualifying in 1988. She was awarded a PhD in leukaemia biology from the Newcastle University in 2000, where she also completed her postgraduate training in paediatric oncology. After 5 years as a Senior Lecturer/Honorary Consultant in Paediatric Oncology at the University of Bristol, she moved to Birmingham in 2007 to further develop her research in childhood acute leukaemias and lymphomas, focused on pre-clinical models and early phase drug development trials.

Pamela is President of the European Society for Paediatric Oncology (SIOP Europe) since January 2019. She is also Board member of the European consortium for Innovative Therapeutics for Children with Cancer (ITCC); developing new treatments for childhood cancers, and through international partnerships, is Chairman of ITCC's Sponsor Institution Committee. In her previous role as vice-chair of the SIOPE Clinical Research Council, she was engaged in raising awareness of the regulatory challenges facing academic trials for children with cancer; supporting crucial amendments to the new EU Clinical Trial Regulation and now, alongside Professor Grazia Valsecchi, she is leading the establishment of SIOPE's Clinical Trials Facilitation Platform to support SIOPE Clinical Study Groups in delivering multi-national clinical trials within the European regulatory framework. Pamela is also an active member of the multi-stakeholder forum ACCELERATE, actively supporting the call for revision of the Paediatric Medicines Regulation to enable children and young people with cancer to rapidly access therapeutic innovation.